December 15, 2008
NEUROPTIX CORP. NAMES GERALD D. CAGLE, PH.D., AS CHIEF OPERATING OFFICER
Pioneer in non-invasive eye test for Alzheimer’s adds industry
veteran to executive leadership
Acton, Massachusetts - December 15, 2008 - Neuroptix Corporation, a leading pioneer in the early detection of Alzheimer’s Disease through a non-invasive eye test, today announced that it has named Gerald D. Cagle, Ph.D., as the company's first Chief Operating Officer.
Paul Hartung, President and CEO of Neuroptix, said, "We are delighted to have an industry veteran of Gerald Cagle's caliber as part of our executive leadership at Neuroptix. He brings a wealth of industry experience of direct relevance to our mission of providing a new and reliable ocular-based diagnostic test for Alzheimer's, and we look forward to his leadership as we bring our Sapphire technology toward clinical trials."
"This is a very exciting time for Neuroptix, given the company's recent successful funding round and ramping up of operations as its technology is further developed and matured," Dr. Cagle said, "With scientific projections of the potential Alzheimer's patient population growing exponentially in the coming years, the goal of a non-invasive diagnostic for the disease that could be implemented in a doctor's office is very timely, and can potentially positively impact a huge therapeutic class."
Dr. Cagle most recently served as Senior Vice President of Research and Development and Chief Scientific Officer of Alcon Laboratories, Inc., a subsidiary of Alcon, Inc., the world’s largest eye care company. Starting as a senior scientist in microbiology, he held several positions of increasing responsibility at Alcon, including Vice President of Product Management and Vice President of Regulatory Affairs.
Dr. Cagle received his Bachelor of Science degree from Wayland College in Plainview, Texas. He earned both a Master of Science and a Ph.D. from the University of North Texas in Denton, Texas. Dr. Cagle is the author of numerous peer-reviewed journal articles, and holds several product-related patents.
Dr. Cagle is a member of the American Academy of Ophthalmology and the American Society for Microbiology. He serves on the Wilmer Eye Institute Advisory Council, acts as a delegate to the Association of International Glaucoma Society and is a representative of the Dallas-Fort Worth Health Industries Council and the Board of Directors of TECH Fort Worth.
About Neuroptix Corporation
Neuroptix is creating and developing an innovative, non-invasive eye test to assist in the early diagnosis of Alzheimer’s Disease. Neuroptix’s goal is to provide clinicians with a quick, predictive, reliable, inexpensive and widely available test, enabling early diagnosis and treatment. The company maintains an active interest in collaboration with major pharmaceutical companies to facilitate testing of new Alzheimer’s drugs, and with academic institutions to promote research in this area.
# # #